QT interval prolongation and the risk of malignant ventricular dysrhythmia and/or cardiac arrest: Systematic search and narrative review of risk related to the magnitude of QT interval length

被引:6
|
作者
Robison, Lauren B. [1 ]
Brady, William J. [2 ]
Robison, Robert A. [3 ]
Charlton, Nathan [4 ]
机构
[1] Univ Virginia, Sch Med, Charlottesville, VA 22903 USA
[2] Univ Virginia, Sch Med, Dept Emergency Med, Charlottesville, VA 22903 USA
[3] Elder Res Inc, Charlottesville, VA 22903 USA
[4] Univ Virginia, Sch Med, Dept Emergency Med, Div Med Toxicol, Charlottesville, VA 22903 USA
关键词
QT interval; QT interval prolongation; Ventricular dysrhythmia; Malignant ventricular dysrhythmia; Cardiac arrest; Prediction; CORONARY-ARTERY-DISEASE; SUDDEN-DEATH RISK; PREDICTORS; MORTALITY; DURATION;
D O I
10.1016/j.ajem.2021.05.032
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Prolongation of the QTc interval is associated with an increased risk of malignant ventricular dysrhythmias, such as ventricular tachycardia (VT), and sudden cardiac death. The quantifiable risk rates of adverse dysrhythmic outcome in relation to specific QTc interval length are not known. We conducted a literature review on the topic of QT interval prolongation in adult patients and the associated risk of malignant dysrhythmic event. We specifically formulated our literature search and subsequent literature review to address the following question: Can the clinician identify specific QTc intervals at which a specific quantifiable risk of malignant dysrhythmic event (malignant ventricular dysrhythmia and/or cardiac arrest) occurs in an undifferentiated adult patient population? In the literature search, we identified 701 studies; upon review using specific, pre-determined inclusion criteria, we identified 16 articles for inclusion in the review. From this literature, we were unable to answer the question in a quantifiable manner and only noted that the risk of malignant dysrhythmic event increases with progressively longer QTc interval. The current literature on this topic is inadequate to answer this important question due to heterogenous study methodology, patient populations, endpoints, and periods of observation. Additional prospective research is required on this topic, aimed at addressing the important issue of specific, quantifiable risk and its relation to degree of prolongation of the QTc interval. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 37 条
  • [21] Effectiveness of a Clinical Decision Support System for Reducing the Risk of QT Interval Prolongation in Hospitalized Patients
    Tisdale, James E.
    Jaynes, Heather A.
    Kingery, Joanna R.
    Overholser, Brian R.
    Mourad, Noha A.
    Trujillo, Tate N.
    Kovacs, Richard J.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2014, 7 (03): : 381 - 390
  • [22] Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?
    Buss, Vera H.
    Lee, Kayla
    Naunton, Mark
    Peterson, Gregory M.
    Kosari, Sam
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [23] Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective
    Pollard, C. E.
    Valentin, J-P
    Hammond, T. G.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) : 1538 - 1543
  • [24] Expert system-based application for fatal ventricular arrhythmia risk level estimation based on QT-Interval prolongation
    Galan, Sebastian Garcia
    Cabrera, Jose Angel
    Marchewka, Adam
    Exposito, J. Enrique Munoz
    Cruz, Juan de la Torre
    Candeas, Pedro Vera
    Serrano, F. J. Rodriguez
    Orti, Julio J. Carabias
    Quesada, Francisco J. Canadas
    Campos, Raul Mata
    Reyes, Nicolas Ruiz
    Lendinez, Alfonso Cruz
    EXPERT SYSTEMS WITH APPLICATIONS, 2024, 255
  • [25] Relationship between a risk score for QT interval prolongation and mortality across rural and urban inpatient facilities
    Tan, Malinda S.
    Heise, C. William
    Gallo, Tyler
    Tisdale, James E.
    Woosley, Raymond L.
    Antonescu, Corneliu C.
    Gephart, Sheila M.
    Malone, Daniel C.
    JOURNAL OF ELECTROCARDIOLOGY, 2023, 77 : 4 - 9
  • [26] Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System
    Shao, Haixia
    Shi, Dawei
    Dai, Ying
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (04) : 1386 - 1392
  • [27] QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France
    Perrin-Terrin, Aurelie
    Pathak, Atul
    Lapeyre-Mestre, Maryse
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 (04) : 503 - 510
  • [28] Paced QT interval as a risk factor for new-onset left ventricular systolic dysfunction and cardiac death after permanent pacemaker implantation
    Cho, Eun Jeong
    Park, Seung-Jung
    Park, Kyoung Min
    On, Young Keun
    Kim, June Soo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 203 : 158 - 163
  • [29] Prolongation of the heart rate-corrected QT interval is associated with cardiovascular diseases: Systematic review and meta-analysis
    Welten, Sabrina J. G. C.
    Elders, Petra J. M.
    Remmelzwaal, Sharon
    Doekhie, Roos
    Kee, Kok Wai
    Nijpels, Giel
    van der Heijden, Amber A.
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2023, 116 (02) : 69 - 78
  • [30] Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors
    Letsas, Konstantinos P.
    Efremidis, Michalis
    Kounas, Stavros P.
    Pappas, Loukas K.
    Gavrielatos, Gerasimos
    Alexanian, Ioannis P.
    Dimopoulos, Nikolaos P.
    Filippatos, Gerasimos S.
    Sideris, Antonios
    Kardaras, Fotis
    CLINICAL RESEARCH IN CARDIOLOGY, 2009, 98 (04) : 208 - 212